Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by a laboratory test, with a specific genetic change in their tumor called a homozygous MTAP deletion, and who are willing to provide a tumor tissue sample at the start of the trial for confirmation of this genetic change.
- People whose NSCLC has spread or is at an advanced stage that cannot be cured, and whose cancer has continued to grow after receiving previous treatments.
- People who have at least one tumor that can be measured on a scan, according to standard measurement guidelines.
- People whose scans show clear evidence that their cancer has grown or spread since their most recent treatment.
- People who are generally well enough to carry out light activity and care for themselves, based on a standard health rating scale (a score of 0 or 1 on the ECOG scale).
- People who are 18 years of age or older (or the minimum legal age of consent in the country where the trial is taking place) at the time of signing the consent form.
- People who are able to swallow tablets whole, without chewing or crushing them.
Who may not be able to join:
- People who currently have active cancer spread to the brain, or cancer affecting the lining of the brain or spinal cord.
- People who have a history of stomach or digestive problems — such as uncontrolled nausea, vomiting, or difficulty absorbing food and medications — that could affect how the study treatment is absorbed or make swallowing oral medications difficult.
- People who have previously been treated with a specific type of drug known as a PRMT5 or MAT2A inhibitor.
- People who have a known serious allergic reaction to the study treatment or any of its ingredients.
- Additional eligibility criteria are defined in the study protocol (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Australian sites
+61 2 4632 5500
+61 2 85140594
(+61) 731762111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.